Human Immunodeficiency Virus or HIV is a harmful virus that can result in even taking the life of an individual infected. HIV vaccine is an ultimate prevention and control strategy for AIDS. The primary concept behind all HIV vaccines is to encourage the human immune system to fight HIV. The vaccine could be effective in either of two ways including “preventive” vaccine and “therapeutic” vaccines. Preventive HIV vaccine is given to individual who do not have HIV, and therapeutic HIV vaccine is given to individual who already have HIV. The goal of a therapeutic HIV vaccine is to strengthen a patient’s immune response to the HIV that is already in the patient’s body. Researchers are discovering the use of therapeutic HIV vaccines to eliminate the need for antiretroviral therapy (ART) while still keeping imperceptible levels of HIV and to slow down the progression of HIV infection.
According to study, “Global HIV Vaccines Market Size study, by Type (Acute Paronychia, Chronic Paronychia, Candidal Paronychia, Pyogenic Paronychia), By Antibiotics (Mupirocin Ointment, Fusidic Acid Ointment, Gentamicin Ointment, Dicloxacillin, Others) and Regional Forecasts 2018-2025” the key companies operating in the global HIV vaccines market are AlphaVax, Bionor Pharmaceuticals Asa, Antigen Express, Crucell Pharmaceutical, Argo Therapeutic Inc., Genetic Immunity, Celldex Therapeutics, GeoVax Labs, FIT Biotech, Immune Response Biopharma, GeneCure LLC, Inovio Pharmaceuticals Inc., GenVec Inc., GlaxoSmithKline Plc., Novartis, Oncolys Biopharma, Janssen Global Services LLC, Profectus Biosciences, PaxVax Corp., TVAX Biomedical, Sanofi.
Based on type, market is segmented into acute paronychia, candidal paronychia, chronic paronychia and pyogenic paronychia. In acute paronychia, the causative organisms are generally Staphylococcus aureus or streptococci and, less commonly Pseudomonas or Proteus species. Based on route of administration, market is segmented into oral administration, intramuscular & subcutaneous administration and others. Based on antibiotics, market is segmented into mupirocin ointment, gentamicin ointment, fusidic acid ointment, dicloxacillin, and others. In addition, based on application, market is segmented into research institutes and others.
The market is driven by increase in prevalence of HIV infection due to prostitution, followed by rise in infectious diseases, increase in expenditure on research & development (R&D), rise in company initiatives to enhance vaccine research & development (R&D), growth in non-governmental organizations to help the remote areas where medicine cannot reach, rise in number of new entrants in the market and growth in awareness among people about HIV. However, growth in number of trial failure and expensive & multifaceted studies may impact the market. Moreover, increase in number of new entrants and high growth prospects in emerging markets are key opportunities for market.
Based on geography, the North-American is the leading region in HIV vaccines market owing to presence of new technologies and higher adoption of various HIV Vaccines trials in the region. The European and Asian-Pacific regions are also estimated to witness higher growth rate due to rise in prevalence of HIV diseases, growth in government support for vaccine development and increase in healthcare sectors over the forecast period. It is expected that the market will be reached at fast speed as a result of rise in government initiatives to promote vaccines during the forecast period.
For more information, click on the link below:
Global HIV Vaccines Market
Ankur Gupta, Head Marketing & Communications